Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

New ADC targets on the horizon

Date

07 Mar 2023

Session

Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Presenters

Antoine Hollebecque

Authors

A. Hollebecque

Author affiliations

Ditep, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

07 Mar 2023

Introduction

Presenter: Solange Peters

Session: Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Resources:

Webcast

07 Mar 2023

An overview of current approaches utilizing ADCs

Presenter: Solange Peters

Session: Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Resources:

Webcast

07 Mar 2023

Leveraging immune stimulatory ADCs to target immune checkpoints

Presenter: Elena Garralda Cabanas

Session: Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Resources:

Webcast

07 Mar 2023

Q&A and discussion

Presenter: Solange Peters

Session: Seagen - ADCs’ journey into clinical use - Key considerations for improved outcomes

Resources:

Webcast